Compile Data Set for Download or QSAR
Report error Found 144 Enz. Inhib. hit(s) with all data for entry = 10439
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370388(US10233189, Example 81 | US10787457, Example 81 | ...)
Affinity DataIC50: 0.0400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370382(US10233189, Example 79 | US10787457, Example 79 | ...)
Affinity DataIC50: 0.0700nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370385(US10233189, Example 80 | US10787457, Example 80 | ...)
Affinity DataIC50: 0.0900nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370400(US10233189, Example 85 | US10787457, Example 85 | ...)
Affinity DataIC50: 0.100nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370397(US10233189, Example 84 | US10787457, Example 84 | ...)
Affinity DataIC50: 0.100nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370372(US10233189, Example 76 | US10787457, Example 76 | ...)
Affinity DataIC50: 0.140nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370403(US10233189, Example 86 | US10787457, Example 86 | ...)
Affinity DataIC50: 0.150nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370341(US10233189, Example 35 | US10787457, Example 35 | ...)
Affinity DataIC50: 0.150nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370369(US10233189, Example 75 | US10787457, Example 75 | ...)
Affinity DataIC50: 0.150nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370379(US10233189, Example 78 | US10787457, Example 78 | ...)
Affinity DataIC50: 0.150nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370416(US10233189, Example 63 | US10787457, Example 63 | ...)
Affinity DataIC50: 0.150nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370342(US10233189, Example 66 | US10787457, Example 66 | ...)
Affinity DataIC50: 0.150nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370391(US10233189, Example 82 | US10787457, Example 82 | ...)
Affinity DataIC50: 0.150nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370345(US10233189, Example 67 | US10787457, Example 67 | ...)
Affinity DataIC50: 0.150nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM464419(US10787457, Example 52 | US11236096, Example 52 | ...)
Affinity DataIC50: 0.160nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM464418(US10787457, Example 51 | US11236096, Example 51 | ...)
Affinity DataIC50: 0.170nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370394(US10233189, Example 83 | US10787457, Example 83 | ...)
Affinity DataIC50: 0.170nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370377(US10233189, Example 50 | US10787457, Example 50 | ...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM464415(US10787457, Example 48 | US11236096, Example 48 | ...)
Affinity DataIC50: 0.210nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM464421(US10787457, Example 54 | US11236096, Example 54 | ...)
Affinity DataIC50: 0.230nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370418(US10233189, Example 65 | US10787457, Example 65 | ...)
Affinity DataIC50: 0.230nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370360(US10233189, Example 72 | US10787457, Example 72 | ...)
Affinity DataIC50: 0.266nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370402(US10233189, Example 58 | US10787457, Example 58 | ...)
Affinity DataIC50: 0.270nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM535778(US11236096, Example 56)
Affinity DataIC50: 0.279nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM535758(US11236096, Example 34)
Affinity DataIC50: 0.290nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370363(US10233189, Example 73 | US10787457, Example 73 | ...)
Affinity DataIC50: 0.320nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370348(US10233189, Example 68 | US10787457, Example 68 | ...)
Affinity DataIC50: 0.337nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM464422(US10787457, Example 55 | US11236096, Example 55 | ...)
Affinity DataIC50: 0.360nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370357(US10233189, Example 71 | US10787457, Example 71 | ...)
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370404(US10233189, Example 28 | US10787457, Example 28 | ...)
Affinity DataIC50: 0.400nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370401(US10233189, Example 27 | US10787457, Example 27 | ...)
Affinity DataIC50: 0.430nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370351(US10233189, Example 69 | US10787457, Example 69 | ...)
Affinity DataIC50: 0.460nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM464413(US10787457, Example 46 | US11236096, Example 46 | ...)
Affinity DataIC50: 0.480nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370405(US10233189, Example 59 | US10787457, Example 59 | ...)
Affinity DataIC50: 0.510nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370368(US10233189, Example 47 | US10787457, Example 47 | ...)
Affinity DataIC50: 0.590nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370366(US10233189, Example 74 | US10787457, Example 74 | ...)
Affinity DataIC50: 0.610nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370407(US10233189, Example 29 | US10787457, Example 29 | ...)
Affinity DataIC50: 0.610nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM464420(US10787457, Example 53 | US11236096, Example 53 | ...)
Affinity DataIC50: 0.760nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM464412(US10787457, Example 45 | US11236096, Example 45 | ...)
Affinity DataIC50: 0.788nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370354(US10233189, Example 70 | US10787457, Example 70 | ...)
Affinity DataIC50: 0.790nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370411(US10233189, Example 61 | US10787457, Example 61 | ...)
Affinity DataIC50: 0.830nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370344(US10233189, Example 36 | US10787457, Example 36 | ...)
Affinity DataIC50: 1nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370398(US10233189, Example 26 | US10787457, Example 26 | ...)
Affinity DataIC50: 1nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370389(US10233189, Example 22 | US10787457, Example 22 | ...)
Affinity DataIC50: 1.07nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370375(US10233189, Example 77 | US10787457, Example 77 | ...)
Affinity DataIC50: 1.35nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370399(US10233189, Example 57 | US10787457, Example 57 | ...)
Affinity DataIC50: 1.47nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370350(US10233189, Example 38 | US10787457, Example 38 | ...)
Affinity DataIC50: 1.48nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370353(US10233189, Example 39 | US10787457, Example 39 | ...)
Affinity DataIC50: 1.53nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370361(US10233189, Example 11 | US10787457, Example 11 | ...)
Affinity DataIC50: 1.73nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM370415(US10233189, Example 33 | US10787457, Example 33 | ...)
Affinity DataIC50: 1.86nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
US Patent

Displayed 1 to 50 (of 144 total ) | Next | Last >>
Jump to: